Skip to main content
. 2020 Mar 15;8(1):e000943. doi: 10.1136/bmjdrc-2019-000943

Figure 1.

Figure 1

Flow diagram showing patients with diabetes mellitus enrolled in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes (ACCELERATE) trial and their assignment to treatment evacetrapib or placebo.